<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>The Lancet on World Doctors Alliance</title>
    <link>https://www.worlddoctorsalliance.com/tags/the-lancet/</link>
    <description>Recent content in The Lancet on World Doctors Alliance</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <lastBuildDate>Wed, 23 Dec 2020 19:06:14 +0000</lastBuildDate>
    
	<atom:link href="https://www.worlddoctorsalliance.com/tags/the-lancet/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Use of Adenovirus Type5 Vectored Vaccines a Cautionary tale</title>
      <link>https://www.worlddoctorsalliance.com/blog/use-of-adenovirus-type5-vectored-vaccines-a-cautionarytale/</link>
      <pubDate>Wed, 23 Dec 2020 19:06:14 +0000</pubDate>
      
      <guid>https://www.worlddoctorsalliance.com/blog/use-of-adenovirus-type5-vectored-vaccines-a-cautionarytale/</guid>
      <description>We are writing to express concern about the use of a recombinant adenovirus type-5 (Ad5) vector for a COVID-19 phase 1 vaccine study,1
and subsequent advanced trials. Over a decade ago, we completed the Step and Phambili phase 2b studies that evaluated an Ad5 vectored HIV-1 vaccine administered in three immunisations for efficacy against HIV-1 acquisition.2,3
Both international studies found an increased risk of HIV-1 acquisition among vaccinated men.2, 4</description>
    </item>
    
  </channel>
</rss>